Disease Report: Parkinson's disease


Groups and Companies
Funding
Standard of Care
Unmet Medical Need
Novel Modalities and Combinations
Symptoms Evidence
Symptoms Targets
Pathogenesis Evidence
Pathogenesis Targets
Assays and Models

Certainly! Here is a comprehensive, well-sourced answer to your question about patient groups, academic/research groups, and companies developing drugs for Parkinson’s disease. Each entry includes a summary and a direct source link.

1. Patient groups:


2. Academic groups and institutions:


3. Companies developing a drug:


4. Additional context:

  • Collaborative Initiatives: The Critical Path for Parkinson’s and Parkinson’s Virtual Biotech are major collaborative efforts involving patient groups, academic researchers, and pharmaceutical companies to accelerate drug development and clinical trials.
  • Global Reach: While many organizations are U.S.-based, there are significant efforts in Europe (Parkinson’s Europe, Parkinson’s UK, BIAL, Neurolixis) and Australia (Garvan Institute).
  • Diversity of Approaches: Companies are developing a wide range of therapies, from traditional small molecules to gene therapies, wearable devices, and AI-powered diagnostics.

5. References:


If you need more detail on any specific group, research center, or company, or want to know about a particular drug candidate, let me know!